Forge Nano and Nanexa have signed a joint development agreement to scale up manufacturing for Nanexa's PharmaShell drug delivery platform. This collaboration aims to establish large-scale GMP-compliant ALD manufacturing capabilities, which could accelerate the development and commercialization of PharmaShell-enabled products, including those with Moderna and other partners.
Forge Nano, a merger partner of Archimedes Tech SPAC Partners II, and Nanexa have entered a joint development agreement to create large-scale GMP-compliant ALD manufacturing equipment for Nanexa's PharmaShell drug delivery platform. This collaboration is significant because it addresses a critical bottleneck in pharmaceutical development: scalable manufacturing for advanced drug delivery systems. For Forge Nano, it expands their ALD expertise into the pharmaceutical sector, a new and potentially lucrative market. For Nanexa, it provides the infrastructure and know-how to accelerate the clinical development and potential commercialization of its PharmaShell-enabled products, including its internal pipeline, a license agreement with Moderna, and other undisclosed collaborations. In the short term, this is a positive development for both companies, signaling progress in their respective technologies. Long-term, successful development and regulatory approvals could lead to significant revenue streams, but commercialization remains subject to these factors. Traders should note the potential for increased manufacturing capacity to de-risk future product launches for Nanexa and its partners.